daglutril (KC 12615) / Abbott, AbbVie - LARVOL DELTA

Endopeptidase inhibition a potential new option to target erectile dysfunction? An in vitro study (AUA 2018) - "...It was the aim of the study to elucidate the in vitro effects of the endopeptidase inhibitor KC 12615 on the relaxation of CC induced by CNP or VIP and the contraction mediated by Big ET-1... The inhibition of endopeptidase activity can antagonize the contraction of human penile erectile tissue induced by Big ET-1. These findings might be of significance with regard to future pharmacological treatment options for male ED, in particular in certain conditions where a generalized endothelial dysfunction exists (such as diabetes mellitus, systemic vascular sclerosis)."

Preclinical • Atherosclerosis • Biosimilar • Diabetes • Erectile Dysfunction

Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis. (PubMed, Front Pharmacol) - "Prucalopride, rolipram, fenofibrate, fluoxetine, simvastatin, daglutril, and resveratrol were investigated as potential candidate drugs to suppress cytokine-induced astrocytic ET-1 production. Our in vitro model can be a useful screening tool in the development of new drugs to suppress astrocytic ET-1 production. The effect of simvastatin was for the most part mediated via the mevalonate pathway, suggesting that this might be an interesting target for further drug development."

Journal • EDN1 • IL10